River Road Asset Management LLC Cuts Stock Position in Royalty Pharma PLC $RPRX

Posted by Stanley Muller on Jun 19th, 2026

River Road Asset Management LLC decreased its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 3.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 518,654 shares of the biopharmaceutical company’s stock after selling 20,359 shares during the period. River Road Asset Management LLC’s holdings in Royalty Pharma were worth $20,041,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in RPRX. Royal Bank of Canada increased its holdings in Royalty Pharma by 367.7% in the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after purchasing an additional 160,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock worth $2,490,000 after purchasing an additional 13,489 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of Royalty Pharma during the first quarter worth about $264,000. Intech Investment Management LLC boosted its position in shares of Royalty Pharma by 41.0% in the first quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 13,951 shares during the period. Finally, Invesco Ltd. boosted its position in shares of Royalty Pharma by 21.4% in the second quarter. Invesco Ltd. now owns 1,559,378 shares of the biopharmaceutical company’s stock worth $56,184,000 after buying an additional 274,960 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Royalty Pharma

In related news, Director Gregory Norden sold 3,045 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the transaction, the director owned 191,803 shares in the company, valued at $10,165,559. The trade was a 1.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $52.75, for a total value of $721,831.00. Following the transaction, the executive vice president owned 18,197 shares of the company’s stock, valued at approximately $959,891.75. The trade was a 42.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 199,185 shares of company stock worth $10,082,926. 18.84% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on RPRX shares. UBS Group increased their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Morgan Stanley boosted their price target on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Weiss Ratings cut Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. Citigroup increased their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma has an average rating of “Buy” and an average price target of $53.71.

View Our Latest Stock Report on RPRX

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $52.96 on Friday. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a fifty-two week low of $34.08 and a fifty-two week high of $56.50. The firm has a 50-day simple moving average of $52.07 and a 200 day simple moving average of $46.01. The company has a market cap of $30.50 billion, a PE ratio of 36.03, a P/E/G ratio of 1.48 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The firm had revenue of $630.58 million for the quarter, compared to analysts’ expectations of $881.69 million. On average, sell-side analysts anticipate that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date was Friday, May 15th. Royalty Pharma’s dividend payout ratio is presently 63.95%.

Royalty Pharma Profile

(Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.